LataMed AI Corp. Forward Stock Split Takes Effect, Signaling Corporate Restructuring

LataMed AI Corp. (OTC: LMEDD) announced that its 5-for-1 forward stock split became effective at the opening of trading following publication on the FINRA Daily List. The stock is now trading under the temporary symbol LMEDD, which is expected to revert to LMED after approximately 20 business days. The split is part of a broader corporate action that includes a mandatory share exchange and a new CUSIP number, 21116R404, replacing the previous CUSIP 21116R305.

The forward stock split increases the number of outstanding shares, potentially enhancing liquidity and making the stock more accessible to a broader investor base. For shareholders holding shares through brokerage accounts or in electronic book-entry form, no action is required, as the corporate action is processed automatically. Those with physical stock certificates are not required to immediately surrender them, but when presented for transfer, sale, or exchange, they will be exchanged under the new CUSIP.

Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., emphasized that the split is a milestone for the company. He stated that it reflects the company's progress and commitment to its long-term strategy, which includes expanding its telemedicine platform and pursuing commercialization of its AI platforms: CardioAI, PulmoAI, and NeuroAI. These platforms are designed to address healthcare challenges in emerging markets, particularly in Latin America.

The corporate restructuring comes as LataMed AI continues to develop its digital health infrastructure, focusing on telehealth, healthcare coordination, analytics, and AI-enabled solutions. The company's strategy targets underserved regions, aiming to improve healthcare access, patient engagement, and provider coordination. The forward stock split may signal confidence in the company's future prospects and its ability to execute on its business plan.

Investors are reminded that the company's securities involve high risk, and decisions should be based on information in SEC filings. The company encourages shareholders with questions to contact their brokerage firm or the transfer agent. Additional information is available on the company's website at https://latamed.ai and SEC filings at www.sec.gov.

The forward stock split and share exchange are expected to be fully processed within the next 20 business days, after which the trading symbol will revert to LMED. This event is a key step in LataMed AI's corporate development as it seeks to advance its AI-driven healthcare solutions and capture market opportunities in emerging economies.